Bonfield, T.L.; Sutton, M.T.; Fletcher, D.R.; Reese-Koc, J.; Roesch, E.A.; Lazarus, H.M.; Chmiel, J.F.; Caplan, A.I.
Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF). Pharmaceuticals 2023, 16, 220.
https://doi.org/10.3390/ph16020220
AMA Style
Bonfield TL, Sutton MT, Fletcher DR, Reese-Koc J, Roesch EA, Lazarus HM, Chmiel JF, Caplan AI.
Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF). Pharmaceuticals. 2023; 16(2):220.
https://doi.org/10.3390/ph16020220
Chicago/Turabian Style
Bonfield, Tracey L., Morgan T. Sutton, David R. Fletcher, Jane Reese-Koc, Erica A. Roesch, Hillard M. Lazarus, James F. Chmiel, and Arnold I. Caplan.
2023. "Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF)" Pharmaceuticals 16, no. 2: 220.
https://doi.org/10.3390/ph16020220
APA Style
Bonfield, T. L., Sutton, M. T., Fletcher, D. R., Reese-Koc, J., Roesch, E. A., Lazarus, H. M., Chmiel, J. F., & Caplan, A. I.
(2023). Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF). Pharmaceuticals, 16(2), 220.
https://doi.org/10.3390/ph16020220
